Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
17
1kṀ6697resolved Jan 2
Resolved
NO1D
1W
1M
ALL
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
This question is managed and resolved by Manifold.
Get
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ169 | |
| 2 | Ṁ98 | |
| 3 | Ṁ73 | |
| 4 | Ṁ30 | |
| 5 | Ṁ28 |
Sort by:
made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl
Related questions
Related questions
Will semaglutide be taken off FDA's drug shortage list in 2025?
92% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
17% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
81% chance